Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people
infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading …

This review article examines the structure and replication cycle of hepatitis B virus and
discusses the natural history of primary infection, the mechanisms of clearance of the virus …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …

These guidelines have been written to assist physicians and other health care providers in
the recognition, diagnosis, and management of patients chronically infected with the …

Hepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT)
levels to> 5 times the upper limit of normal during chronic hepatitis B virus (HBV) infection, is …

More effective and less resistance-prone antiviral agents are now available to treat hepatitis
B virus (HBV) infection. Profound, durable, therapeutic HBV DNA suppression to slow and …

Background Entecavir is a potent and selective guanosine analogue with significant activity
against hepatitis B virus (HBV). Methods In this phase 3, double-blind trial, we randomly …

Chronic hepatitis B is caused by persistent infection with the hepatitis B virus (HBV), a
unique DNA virus that replicates through an RNA intermediate produced from a stable …

BACKGROUND & AIMS: The GLOBE trial has compared the efficacy and safety of
telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B …

Background & aims: Data on thelong-term safety of lamivudine are limited. The aim of this
analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and …